Delayed encephalopathy due to acute carbon monoxide poisoning (DEACMP) is a serious complication of acute carbon monoxide poisoning. Patients with DEACMP often present with cognitive impairment, abnormal mental behavior, extrapyramidal system symptoms, pyramidal system symptoms, and may also have focal cortical dysfunction, which is closely related to the poor prognosis of the patients. Current research shows that the occurrence of DEACMP is related to multiple factors such as immune disorders, and glucocorticoids can exert certain therapeutic effects through immunosuppression. This article reviews the risk factors of DEACMP, the clinical research progress and possible mechanisms of glucocorticoid treatment for DEACMP, providing more references for the clinical treatment of DEACMP.
Parkinson’s disease is a common neurodegenerative disorder with continuously rising incidence rates. Existing pharmacological treatments have complications and cannot halt disease progression. Transcranial focused ultrasound stimulation (tFUS), as a novel neuromodulation technology, demonstrates unique advantages in Parkinson’s disease treatment. tFUS exerts multiple effects through mechanical mechanisms at multiple levels, including protecting dopaminergic neurons, regulating neurotransmitter systems, and improving neural circuit function. Preclinical studies have confirmed its potential in improving both motor and non-motor symptoms, and early clinical studies have shown good safety profiles. However, the clinical translation of tFUS still faces challenges such as parameter optimization and individualized treatment protocols, requiring validation of long-term efficacy through large-scale clinical trials.